Description: Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
Home Page: www.biomindlabs.com
Building Ceibo Of. 002
Canelones,
Uruguay
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Alejandro Antalich | CEO & Director |
| Mr. Oscar Alejandro Leon | CFO & Director |
| Ms. Paola Diaz Dellavalle Ph.D. | Chief Scientific Officer |
| Mr. Juan Presa | Chief Legal Officer |
| Ms. Magdalena Alvarez M.A. | Head of Communication |
| Mr. Martin Daners | Head of Quality Assurance & Regulatory Affairs |
| Dr. Marcelo Falchi | Head of the Psychiatry Research Unit |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 143.1468 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |